Advertisement

Surgery Today

, Volume 29, Issue 3, pp 204–208 | Cite as

Apoptosis and proliferative activity in thyroid tumors

  • Akira Yoshida
  • Yoshiyasu Nakamura
  • Toshio Imada
  • Tarou Asaga
  • Akio Shimizu
  • Maoki Harada
Original Articles

Abstract

To clarify the growth mechanisms of thyroid tumors, we examined apoptotic cells in 61 thyroid tumors, consiting of 14 adenomas, 35 papillary carcinomas, 4 follicular carcinomas, and 8 undifferentiated carcinomas, using terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate digoxigenin-nick end labeling (TUNEL). The proliferative activity was also evaluated immunohistochemically using the monoclonal antibody to Ki-67 antigen (MIB-1) in the same tumors. The apoptotic index (AI) was expressed as a percentage of the TUNEL-positive cells in the tumor cells, and a proliferation index (PI), being the percentage of Ki-67 positive cells, was calculated for each tumor. The overall level of AI was very low in all histotypes of the thyroid tumors analyzed, the mean AI being 0.5±0.4 in adenoma, 0.4±0.3 in differentiated carcinoma, and 1.8±1.5 in undifferentiated carcinoma. The PI in the thyroid tumor subtypes was significantly lower in adenoma and differentiated carcinoma, at 0.5 ±0.7 and 1.1±0.7, respectively, than that in undifferentiated carcinoma at 14.5±3.7 (P<0.05). There was no correlation between clinicopathological factors and AI or PI in differentiated thyroid carcinoma. Our findings suggest that apoptosis occurs infrequently in thyroid tumors, and that proliferative activity markedly differs according to the thyroid tumor subtypes. Moreover, the ratio between proliferating cells and apoptotic cells may reflect thyroid tumor progression.

Key Words

thyroid tumor apoptosis TUNEL MIB-1 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Garcia-Martine V, Macias D, Ganan Y, Garcia-Lobo JM, Francia MV, Fernandez-Teran MA, Hurle JM (1993) Internucleosomal DNA fragmentation and programmed cell death (apoptosis) in the interdinital tissue of the embryonic leg bud. J Cell Sci 106:201–208Google Scholar
  2. 2.
    Cohen JJ (1991) Programmed cell death in the immune system. Adv Immunol 50:55–85CrossRefPubMedGoogle Scholar
  3. 3.
    Wylli AH (1992) Apoptosis and the regulation of cell numbers in normal and neoplastic tissue: an overview. Cancer Metastas Rev 11:95–103CrossRefGoogle Scholar
  4. 4.
    Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501CrossRefPubMedGoogle Scholar
  5. 5.
    Hidinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumors, edn. 2, no. 11. In: International histological classification of tumors. World Health Organization. Springer. BerlinGoogle Scholar
  6. 6.
    Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid: a clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855CrossRefPubMedGoogle Scholar
  7. 7.
    Laster SM, Wood JG, Gooding LR (1988) Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141:2629–2634PubMedGoogle Scholar
  8. 8.
    Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, and Gerdes J (1992) Monoclonal antibodies against recombinant part of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cell in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363CrossRefPubMedGoogle Scholar
  9. 9.
    Carcangiu MI, Steeper T, Zampi G, Rosai J (1985) Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 83:135–158PubMedGoogle Scholar
  10. 10.
    Staunton MJ, Gaffney EF (1995) Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 103:300–307PubMedGoogle Scholar
  11. 11.
    Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A (1997) Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537–541PubMedGoogle Scholar
  12. 12.
    Katoh R, Bray CE, Suzuki K, Komiyama A, Hemmi A, Kawaoi A, Oyama T, Sugai T, Sasou S (1995) Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 26:139–146CrossRefPubMedGoogle Scholar
  13. 13.
    Shimizu T, Usuda N, Yamada T, Sugenoya A, Iida F (1993) proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 71:2807–2812CrossRefPubMedGoogle Scholar
  14. 14.
    Yoshida A, Kamma H, Asaga T, Masuzawa C, Kawahara S, Mimura T, Ito K (1992) Proliferative activity in thyroid tumors. Cancer 69:2548–2552CrossRefPubMedGoogle Scholar
  15. 15.
    Wanebo HJ, Andrews W, Kaiser DL (1981) Thyroid cancer: some basic considerations. Am J Surg 142:474–479CrossRefPubMedGoogle Scholar
  16. 16.
    Bacout F, Asselain B, Savoie JC, D’Hubert, E, Massin JP, Doucet G, Leger A, Garnier H (1988) Multificatorial study of prognostic factors in differentiated thyroid carcinoma and a re-evaluation of the importance of age. Br J Surg 73:274–277CrossRefGoogle Scholar
  17. 17.
    Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Weber J (1979) Risk factors analysis in differentiated thyroid cancer. Cancer 43:810–820CrossRefPubMedGoogle Scholar
  18. 18.
    Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli, J, Parmentier C (1985) Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794–804CrossRefPubMedGoogle Scholar
  19. 19.
    Samaan NA, Maheshwari YK, Nader S, Hill CS, Schultz PN, Haynie TP, Hickey RC, Hickey RC, Clark RL, Goepfert H, Ibanez ML, Litton CE (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 56:1131–1137CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • Akira Yoshida
    • 1
  • Yoshiyasu Nakamura
    • 2
  • Toshio Imada
    • 3
  • Tarou Asaga
    • 1
  • Akio Shimizu
    • 2
  • Maoki Harada
    • 2
  1. 1.Second Division of Surgery Kanagawa Cancer CenterYokohamaJapan
  2. 2.Research Institute, Kanagawa Cancer CenterYokohamaJapan
  3. 3.First Department of Surgery, Yokohama City UniversityUrafune HospitalYokohamaJapan

Personalised recommendations